Belpointe Asset Management LLC Makes New $752,000 Investment in ResMed Inc. $RMD

Belpointe Asset Management LLC acquired a new stake in ResMed Inc. (NYSE:RMD) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,748 shares of the medical equipment provider’s stock, valued at approximately $752,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of ResMed during the 2nd quarter worth approximately $306,452,000. Vanguard Group Inc. grew its stake in shares of ResMed by 1.4% in the second quarter. Vanguard Group Inc. now owns 18,746,925 shares of the medical equipment provider’s stock valued at $4,836,707,000 after acquiring an additional 253,223 shares in the last quarter. Ilex Capital Partners UK LLP bought a new position in shares of ResMed during the second quarter worth approximately $39,306,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of ResMed in the second quarter worth $34,443,000. Finally, Swedbank AB lifted its position in ResMed by 25.4% during the third quarter. Swedbank AB now owns 542,711 shares of the medical equipment provider’s stock worth $148,556,000 after purchasing an additional 109,760 shares during the period. Institutional investors own 54.98% of the company’s stock.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non?GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross?margin improvement and $340M operating cash flow. These metrics support near?term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI?enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near?term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

ResMed Stock Performance

NYSE:RMD opened at $257.76 on Friday. The firm has a market cap of $37.62 billion, a PE ratio of 25.50, a price-to-earnings-growth ratio of 1.73 and a beta of 0.88. The business has a 50 day moving average price of $251.04 and a 200-day moving average price of $263.22. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89. ResMed Inc. has a fifty-two week low of $199.92 and a fifty-two week high of $293.81.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. ResMed had a net margin of 27.53% and a return on equity of 25.68%. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business posted $2.43 earnings per share. ResMed’s quarterly revenue was up 11.0% compared to the same quarter last year. Equities research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be paid a $0.60 dividend. The ex-dividend date is Thursday, February 12th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. ResMed’s payout ratio is currently 24.56%.

Insider Transactions at ResMed

In other ResMed news, Director Witte Jan De sold 2,055 shares of ResMed stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total value of $524,025.00. Following the completion of the sale, the director owned 4,261 shares of the company’s stock, valued at approximately $1,086,555. The trade was a 32.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total value of $497,660.00. Following the completion of the transaction, the director owned 66,773 shares in the company, valued at approximately $16,615,125.59. This trade represents a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 21,594 shares of company stock worth $5,403,495 over the last three months. 0.65% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

RMD has been the subject of several research analyst reports. KeyCorp reissued an “overweight” rating and set a $302.00 target price on shares of ResMed in a research note on Friday. Morgan Stanley set a $305.00 target price on shares of ResMed in a research note on Friday, October 31st. Wells Fargo & Company boosted their target price on shares of ResMed from $265.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Friday. Piper Sandler lifted their target price on shares of ResMed from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, UBS Group restated a “buy” rating and set a $345.00 price target on shares of ResMed in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $297.91.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.